Evolus

Yahoo Finance • 5 days ago

Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization

By Karen Roman Exec Edge sat down with Nadeem Moiz, Chief Executive Officer at Revance, to learn more about the company’s vision in aesthetics, skincare and therapeutics. Exec Edge: Tell us about Revance and the science-powered products... Full story

Yahoo Finance • 11 days ago

Telix Appoints David Gill as Non-Executive Director

MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board ex... Full story

Yahoo Finance • 28 days ago

Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference

Evolus logo Key Points Evolus says the U.S. botulinum toxin market is stabilizing after the 2024 pullback, expecting low-single-digit growth now with a return to mid-single-digit growth by 2027–2028. Its new HA product, Evolysse, is gain... Full story

Yahoo Finance • last month

Evolus posts record rally after Q4 beat

[Close up image of wooden cubes with alphabet Q4 on office desk.] mohd izzuan Evolus (EOLS [https://seekingalpha.com/symbol/EOLS]) shares jumped ~36% on Wednesday, its biggest intraday gain in nearly half a decade, after the maker of Jeuv... Full story

Yahoo Finance • last month

Evolus outlines 2026 revenue guidance of $327M–$337M while expanding international presence and product portfolio

Earnings Call Insights: Evolus (EOLS) Q4 2025 MANAGEMENT VIEW * CEO David Moatazedi described Evolus' focus on a "performance beauty strategy" centered around a cash-pay aesthetic model, emphasizing differentiation through partnerships... Full story

Yahoo Finance • last month

Quant snapshot: Impala Platinum, Turkcell Iletisim lead strong buys as Evolus lag

Information Technology stocks lead the pack on quant strength in the latest screen, posting the highest average ratings among the sectors listed, while Health Care names rank at the bottom. The single highest-rated stock overall is Impala... Full story

Yahoo Finance • 7 months ago

Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer

NEWPORT BEACH, Calif., September 08, 2025--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell a... Full story

Yahoo Finance • 8 months ago

What's going on in today's session

Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SGBX [https://www.chartmill.com/stock/quote/SGBX/profile] 86.14% SAF... Full story

Yahoo Finance • 8 months ago

Here are the top movers in Wednesday's session.

Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TOP GAINERS TICKER CHANGE COMMENT GO [https://www.cha... Full story

Yahoo Finance • 8 months ago

The market is filled with gapping stocks in Wednesday's session.

Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps. [gap] GAP UP STOCKS TICKER CHANGE COMMENT SGBX [https://www.chartmill.com/stock/quote/SGBX... Full story

Yahoo Finance • 8 months ago

Discover the top movers in Wednesday's pre-market session.

As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMME... Full story

Yahoo Finance • 8 months ago

Evolus outlines $700M 2028 revenue target and cost realignment amid market softness

Earnings Call Insights: Evolus, Inc. (EOLS) Q2 2025 MANAGEMENT VIEW * CEO David Moatazedi reported that "our second quarter results came in below expectations, reflecting one of the most challenging market environments we've seen in re... Full story

Yahoo Finance • 8 months ago

Top movers in Tuesday's after hours session

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. [postmarket] GAINERS TICKER CHANGE COMMENT... Full story

Yahoo Finance • 8 months ago

Evolus GAAP EPS of -$0.27 misses by $0.07, revenue of $69.4M misses by $12.64M

* Evolus press release [https://seekingalpha.com/pr/20190054-evolus-reports-second-quarter-2025-financial-results-and-provides-business-updates] (NASDAQ:EOLS [https://seekingalpha.com/symbol/EOLS]): Q2 GAAP EPS of -$0.27 misses by $0.07.... Full story

Yahoo Finance • 8 months ago

Jeuveau shows fast onset and long duration in neurotoxin study

NEWPORT BEACH, Calif. - A landmark independent study published in JAMA Dermatology has directly compared four FDA-approved botulinum toxin products for treating glabellar lines, finding that Jeuveau (prabotulinumtoxinA-xvfs) demonstrated f... Full story

Yahoo Finance • 2 years ago

11 Best Low Price Pharma Stocks To Invest In

In this piece, we will take a look at the 13 best low price pharma stocks to invest in. If you want to skip our overview of the pharma industry and want to skip to the five top low price stocks in this list, then you can skip ahead to 5 Be... Full story

Yahoo Finance • 2 years ago

16 Most Promising Long-Term Stocks According to Analysts

In this piece, we will take a look at the 16 most promising long-term stocks according to analysts. If you want to skip our overview of long term investing, then you can take a look at 5 Most Promising Long-Term Stocks According to Analyst... Full story

Yahoo Finance • 2 years ago

"Extra-Strength" 40U Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting

"Extra-strength" 40U formulation demonstrated a duration of 26 weeks, or 6 months, when measuring the time for a patient to return back to their baseline Glabellar Line score after a single treatment 40U results indicate a similar safety p... Full story

Yahoo Finance • 3 years ago

Q4 2022 Evolus Inc Earnings Call

Participants David Moatazedi; President, CEO & Director; Evolus, Inc. David K. Erickson; VP of IR; Evolus, Inc. Rui Avelar; Chief Medical Officer and Head of Research & Development; Evolus, Inc. Sandra Beaver; CFO; Evolus, Inc. Annabe... Full story

Yahoo Finance • 3 years ago

Evolus to Participate in the Barclays Global Healthcare Conference

NEWPORT BEACH, Calif., February 28, 2023--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its manageme... Full story